Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$56.30
pos +1.34
+2.44%
Today's Range: 54.65 - 56.43 | GILD Avg Daily Volume: 11,721,000
Last Update: 05/17/13 - 4:00 PM EDT
Volume: 13,869,497
YTD Performance: 53.46%
Open: $55.48
Previous Close: $54.96
52 Week Range: $24.12 - $57.10
Oustanding Shares: 1,525,355,825
Market Cap: 85,969,054,297
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 16 16 16
Moderate Buy 2 3 3 3
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.38 1.39 1.39 1.39
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 09/07/04
Price Earnings Ratio: 31.49
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
31.49 31.60 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
35.48% 111.91% 198.36%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.70 0.38 0.11
Net Income 0.00 -0.02 -0.01
EPS -7.60 0.17 0.05
Earnings for GILD:
EBITDA 4.29B
Revenue 9.70B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $0.47 $0.47 $1.90 $2.76
Number of Analysts 3 3 3 3
High Estimate $0.47 $0.48 $1.96 $3.22
Low Estimate $0.46 $0.44 $1.83 $2.36
Prior Year $0.47 $0.47 $1.73 $1.90
Growth Rate (Year over Year) -0.71% -1.75% 9.83% 45.26%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
US_proptrader
US_proptrader: $GILD charts at http://t.co/wjpxyxYK4Z 1652
10 hours ago from Seesmic twhirl
wallstCS
wallstCS: Staples Launches Sports & Art Photo Gallery and 2 More Heavily Traded Stocks to Follow http://t.co/ArF6AirGYP $GILD
10 hours ago from WSCSCustomApp
cdcowan
cdcowan: $GILD is my horse right now.
10 hours ago from Twitter for iPhone
MarketCurrents
MarketCurrents: Gilead Sciences (GILD +2.4%) finishes higher today after UBS raised its price target to $67 from $63 ... http://t.co/yPtUNOf6R0 $GILD
10 hours ago from Seeking Alpha
JohnTuckerPhD
JohnTuckerPhD: @chasingthealpha @JasonCRG That case is more interesting because $GILD has not demonstrated ability to make a competitive PI.
10 hours ago from web
US_proptrader
US_proptrader: $GILD $IDIX $NPSP charts at http://t.co/wjpxyxYK4Z 1614
10 hours ago from Seesmic twhirl
US_proptrader
US_proptrader: $GILD $SAPE charts at http://t.co/wjpxyxYK4Z 1610
11 hours ago from Seesmic twhirl
JohnTuckerPhD
JohnTuckerPhD: @chasingthealpha @JasonCRG I agree mkt is $GILD's to lose, but $IDIX EV is 2.5% of what $GILD paid for $VRUS. Prob. adj. mkt share >5%?
11 hours ago from web
US_proptrader
US_proptrader: $GILD charts at http://t.co/wjpxyxYK4Z 1545
11 hours ago from Seesmic twhirl
COCKRELLGROUP
COCKRELLGROUP: Credit Suisse analyst Ravi Mehrotra made price target changes to: Biogen Idec $BIIB) to $255 from $225; Gilead $GILD to $67 from $60.
11 hours ago from web

bullishGilead Sciences price target and estimates raised at UBS

May 17, 2013 | 7:53 AM EDT

GILD estimates were increased to include tenofovir alafenamide (TAF) after positive feedback from doctors, said UBS. Price target goes to $67.

Biotech's Next Big Thing -- ASCO II

By

Adam Feuerstein

 | May 16, 2013 | 2:09 PM EDT

<I>TheStreet</I> senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.

updateBofA/Merrill Healthcare Conf.

May 15, 2013 | 7:11 AM EDT

Bank of America Merrill Lynch Health Care Conference (Day 2 of 3) - 05/14/13 - 05/16/13 Las Vegas, NV

Off the Charts

By

Scott Redler

 | May 14, 2013 | 7:16 PM EDT

At this rate, the S&P could hit 1700 by the end of the month!

Off the Charts

By

Scott Redler

 | May 13, 2013 | 6:44 PM EDT

We see a lot of short squeezes as money rotates into laggard groups. 

Biotech Makes a Comeback

By

Jim Cramer

 | May 10, 2013 | 12:52 PM EDT

Just a natural change in leadership.

Off the Charts

By

Scott Redler

 | May 9, 2013 | 6:44 PM EDT

Rest is key in bull markets in order to sustain a longer-term rally.

Biotech&#039;s Next Big Thing: ASCO

By

Adam Feuerstein

 | May 9, 2013 | 9:39 AM EDT

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.

updateGILD Investor Mtg.

May 8, 2013 | 7:30 AM EDT

 Gilead Sciences Annual Stockholders Meeting - 1PM

Big Pharma Has Lost Its Way

By

Jim Cramer

 | May 3, 2013 | 7:23 AM EDT

Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.

Columnist Conversation / Market Updates

Isn't it funny?
By

Paul Price

 | May 17, 2013 | 4:14 PM EDT
I haven't heard many "Sell in May and go away" comments over the past two weeks. I wonder why.

Autozone moving counter-trend
By

Paul Price

 | May 17, 2013 | 3:31 PM EDT
Automotive parts and service provided Autozone (AZO) is down $2.51 today even as the broad market hits all-time record l...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.